Volume 5.43 | Oct 31

Mammary Cell News 5.43 October 31, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
Aurora-A Is a Determinant of Tamoxifen Sensitivity Through Phosphorylation of ERα in Breast Cancer
Investigators showed that Aurora-A determines tamoxifen sensitivity by regulation of estrogen receptor (ER)α. Ectopic expression of Aurora-A decreased and depletion of Aurora-A enhanced tamoxifen sensitivity in ERα-positive breast cancer. [Oncogene] Abstract
Read White Paper:  Increase Success Rate Of Compounds In Toxicity Testing
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Therapeutic Targeting of erbB3 with MM-121/SAR256212 Enhances Antitumor Activity of Paclitaxel Against erbB2-Overexpressing Breast Cancer
Researchers studied the antitumor activity of an anti-erbB3 antibody MM-121/SAR256212 in combination with paclitaxel against erbB2-overexpressing breast cancer. [Breast Cancer Res] Abstract | Full Article

T47D Breast Cancer Cells Switch from ER/HER to HER/c-Src Signaling Upon Acquiring Resistance to the Antiestrogen Fulvestrant
Researchers established T47D cell lines resistant to the antiestrogen fulvestrant and analyzed them to explore whether a switch to HER signaling, as seen in fulvestrant resistant MCF-7 cell lines, is a general resistance mechanism. [Cancer Lett] Abstract

Down-Regulation of miR-106b Induced Breast Cancer Cell Invasion and Motility in Association with Overexpression of MMP2
Researchers found matrix metalloproteinase 2 (MMP2) expression in orthotopic tumor tissue to be related to the risk of bone metastasis in breast cancer patients. [Cancer Sci] Abstract

Extra Virgin Olive Oil Potentiates the Effects of Aromatase Inhibitors via Glutathione Depletion in Estrogen Receptor-Positive Human Breast Cancer (MCF-7) Cells
Scientists aimed to investigate whether extra virgin olive oil and oleic acid could enhance the effects of aromatase inhibitors (letrozole and anastrozole) in estrogen receptor-positive MCF-7 cells, as well as to investigate its influence on cytochrome c release and glutathione levels. [Food Chem Toxicol] Abstract

Naphtho[1,2-b]Furan-4,5-Dione Inhibits MDA-MB-231 Cell Migration and Invasion by Suppressing Src-Mediated Signaling Pathways
Investigators showed that naphtho[1,2-b]furan-4,5-dione blocked migration and invasion of MDA-MB-231 breast cancer cells without affecting apoptosis or growth arrest. [Mol Cell Biochem] Abstract

The Expression and Prognosis of Emi1 and Skp2 in Breast Carcinoma: Associated with PI3K/Akt Pathway and Cell Proliferation
Researchers aimed to examine the effect of early mitotic inhibitor-1 (Emi1) over-expression on S-phase kinase protein 2 (Skp2) expression and related signaling pathway in breast cancer. [Med Oncol] Abstract

CLINICAL RESEARCH

Dual HER2 Inhibition in Combination with Anti-VEGF Treatment is Active in Heavily Pretreated HER2-Positive Breast Cancer
Researchers conducted a dose-escalation, phase I study of a combination of trastuzumab, lapatinib and bevacizumab. The subset of patients with metastatic breast cancer was analyzed for safety and response. [ Ann Oncol] Abstract

The Effect of Metformin on Apoptosis in a Breast Cancer Presurgical Trial
Apoptosis was analyzed in core biopsies and in surgical samples from 100 non-diabetic BC patients participating in a randomized trial of metformin versus placebo given for four weeks before surgery. [Br J Cancer] Abstract

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
BOLERO-2 is a phase III, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR+ advanced breast cancer with recurrence/progression during or after nonsteroidal aromatase inhibitors. The primary endpoint was Progression-Free Survival by local investigator review, and was confirmed by independent central radiology review. [Adv Ther] Abstract | Full Article

Watch the Video: Optimize Your ALDHbr Cell Detection with Tissue-Specific ALDEFLUOR™ Protocols
 
REVIEWS
Role of Adipokines and Cytokines in Obesity-Associated Breast Cancer: Therapeutic Targets
Authors discuss different adipokine- and cytokine-mediated molecular signaling pathways involved in obesity-associated breast cancer, available therapeutic strategies and potential therapeutic targets for obesity-associated breast cancer. [Cytokine Growth Factor Rev] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
UB Scientist’s Firm to Develop Promising Breast Cancer Treatment
Through her startup firm, University at Buffalo researcher Kate Rittenhouse-Olson is turning a mouse antibody she created into a promising cancer-fighting therapy for humans. [University at Buffalo] Press Release

OncoMed Pharmaceuticals Initiates First Phase Ib Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) with Paclitaxel in Breast Cancer
The Phase 1b clinical trial is a dose escalation study of the anti-cancer stem cell antibody vantictumab in combination with paclitaxel in patients with first-, second- and third-line, locally advanced or metastatic HER2 negative breast cancer. [OncoMed Pharmaceuticals, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 12th International Congress on Targeted Anticancer Therapies
March 5-7, 2014
Washington, United States

NEW 16th Milan Breast Cancer Conference
June 26-27, 2014
Milan, Italy

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Clinical Trial Manager – Clinical Trials and Statistics Unit (Institute of Cancer Research)

NEW Research Assistant – BREAST-PREDICT (National University of Ireland Galway)

PhD Position – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Medical Center)

Postdoctoral Position – Breast Cancer Research (Karolinska Institute)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Mammary Cell News: Archives | Events | Contact Us